1. , : Development of androgen resistance in prostatic cancer. In , , , (eds): “Prostate Cancer, Part A: Research, Endocrine Treatment, and Histopathology.” (Progress in Clinical and Biological Research, Vol 243A). New York: Alan R. Liss, Inc., 1987, pp 21–31.
2. , : A critical review of the concept of total androgen ablation in the treatment of prostate cancer. In , , , (eds): “Prostate Cancer, Part A: Research, Endocrine Treatment, and Histopathology.” (Progress in Clinical and Biological Research, Vol 243A). New York: Alan R. Liss, Inc., 1987, pp 1–19.
3. Effect of hormones on growth and ATP content of a human prostatic carcinoma cell line, LNCaP-r
4. : Difference in uptake of 3H-estramustine in two human prostatic carcinoma cell lines, LNCaP and LNCaP-r. Urol Res (in press).